Jones Heather A, Metz James M, Devine Pamela, Hahn Stephen M, Whittington Richard
Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA.
Urology. 2002 Feb;59(2):272-6. doi: 10.1016/s0090-4295(01)01491-1.
The use of unconventional medical therapies (UMTs) in the general population has increased dramatically in the past decade. Studies have estimated that 9% to 64% of patients with cancer use UMTs, and many do not disclose this information to their physicians. This study was designed to evaluate the rates of UMT use by patients with prostate cancer revealed by standard versus directed questioning and to identify demographic markers that may predict use.
A prospective study of 287 consecutive patients with cancer presenting to the Department of Radiation Oncology was performed. The prostate cancer population was 29% (84 of 287) of the total cancer patient population. Each patient underwent the standard history interview, including questions regarding prescription and over-the-counter medication. At the completion of the standard history interview, patients were then asked a set of directed questions regarding the use of UMTs.
Of the 84 patients with prostate cancer, 31 (37%) used unconventional therapies. The standard history revealed that 6 (19%) of 31 used UMTs, and directed questioning revealed an additional 25 patients (81%) used UMTs in the study population (P <0.001). Of those using UMTs, 65% used megavitamins, 49% used herbal remedies, 13% used meditation or guided imagery, and 20% used nonherbal natural supplements.
UMT use is prevalent among patients with prostate cancer. Some of these treatments may have a potential biologic impact on tumor behavior, therapeutic endpoints, and measured prostate-specific antigen values. The use of directed questioning during the patient evaluation significantly increases the physician's ability to identify patients with prostate cancer using UMTs.
在过去十年中,普通人群对非常规医学疗法(UMTs)的使用急剧增加。研究估计,9%至64%的癌症患者使用UMTs,且许多患者未将此信息告知其医生。本研究旨在评估通过标准询问与定向询问所揭示的前列腺癌患者使用UMTs的比例,并确定可能预测使用情况的人口统计学指标。
对连续就诊于放射肿瘤学部门的287例癌症患者进行了一项前瞻性研究。前列腺癌患者占癌症患者总数的29%(287例中的84例)。每位患者均接受了标准病史访谈,包括有关处方药和非处方药的问题。在标准病史访谈结束时,接着询问患者一系列有关UMTs使用情况的定向问题。
在84例前列腺癌患者中,31例(37%)使用了非常规疗法。标准病史显示,31例中有6例(19%)使用了UMTs,而定向询问又发现另外25例患者(81%)在研究人群中使用了UMTs(P<0.001)。在使用UMTs的患者中,65%使用了大剂量维生素,49%使用了草药疗法,13%使用了冥想或引导式意象疗法,20%使用了非草药天然补充剂。
UMTs在前列腺癌患者中普遍使用。其中一些治疗可能对肿瘤行为、治疗终点以及所测得的前列腺特异性抗原值具有潜在的生物学影响。在患者评估过程中使用定向询问可显著提高医生识别使用UMTs的前列腺癌患者的能力。